Salem, NH, United States
Salem, NH, United States

Time filter

Source Type

SALEM, N.H. & PHILADELPHIA--(BUSINESS WIRE)--Gamma Medica, a leader in molecular breast imaging (MBI) technology, today announced that Einstein Medical Center Philadelphia has committed to purchase Pennsylvania’s first clinical LumaGEM® Molecular Breast Imaging system. MBI is a secondary screening and diagnostic tool that is particularly useful for women who have dense breast tissue and women with a high risk of being diagnosed with cancer. It is a proven, effective supplementary screening meth


WEST BLOOMFIELD, Mich. & SALEM, N.H.--(BUSINESS WIRE)--Gamma Medica, a leader in molecular breast imaging (MBI) technology, today announced that Henry Ford Health System has purchased Gamma Medica’s LumaGEM Molecular Breast Imaging system. The system is set to be installed by the end of 2016 at Henry Ford West Bloomfield Hospital. The MBI technology will be offered as a secondary screening and diagnostic tool following X-ray mammography, particularly for women with dense breast tissue. This pro


This report studies sales (consumption) of Small Animal Imaging Reagents in Europe market, especially in Germany, UK, France, Russia, Italy, Benelux and Spain, focuses on top players in these countries, with sales, price, revenue and market share for each player in these Countries, covering Bruker Corporation (U.S.) Siemens AG (Germany) Life Technologies Corporation (U.S.) FUJIFILM Holdings Corporation (Japan) Miltenyi Biotec GmbH (Germany) PerkinElmer, Inc. (U.S.) Bioscan, Inc. (U.S.) Mediso Medical Imaging Systems (Hungary) Gamma Medica (U.S.) Aspect Imaging (Israel) View Full Report With Complete TOC, List Of Figure and Table: http://globalqyresearch.com/europe-small-animal-imaging-reagents-market-report-2016 Market Segment by Countries, this report splits Europe into several key Countries, with sales (consumption), revenue, market share and growth rate of Small Animal Imaging Reagents in these countries, from 2011 to 2021 (forecast), like Germany France UK Russia Italy Spain Benelux Split by product type, with sales, revenue, price, market share and growth rate of each type, can be divided into Mri contrasting reagents Ct contrast reagents Ultrasound contrast reagents Nuclear and optical imaging agents Split by application, this report focuses on sales, market share and growth rate of Small Animal Imaging Reagents in each application, can be divided into Pharma companies Research institutions Others Europe Small Animal Imaging Reagents Market Report 2016 1 Small Animal Imaging Reagents Overview 1.1 Product Overview and Scope of Small Animal Imaging Reagents 1.2 Classification of Small Animal Imaging Reagents 1.2.1 Mri contrasting reagents 1.2.2 Ct contrast reagents 1.2.3 Ultrasound contrast reagents 1.2.4 Nuclear and optical imaging agents 1.3 Application of Small Animal Imaging Reagents 1.3.1 Pharma companies 1.3.2 Research institutions 1.3.3 Others 1.4 Small Animal Imaging Reagents Market by Countries 1.4.1 Germany Status and Prospect (2011-2021) 1.4.2 France Status and Prospect (2011-2021) 1.4.3 UK Status and Prospect (2011-2021) 1.4.4 Russia Status and Prospect (2011-2021) 1.4.5 Italy Status and Prospect (2011-2021) 1.4.6 Spain Status and Prospect (2011-2021) 1.4.7 Benelux Status and Prospect (2011-2021) 1.5 Europe Market Size (Value and Volume) of Small Animal Imaging Reagents (2011-2021) 1.5.1 Europe Small Animal Imaging Reagents Sales and Growth Rate (2011-2021) 1.5.2 Europe Small Animal Imaging Reagents Revenue and Growth Rate (2011-2021) 10 Europe Small Animal Imaging Reagents Manufacturers Analysis 10.1 Bruker Corporation (U.S.) 10.1.1 Company Basic Information, Manufacturing Base and Competitors 10.1.2 Small Animal Imaging Reagents Product Type, Application and Specification 10.1.2.1 Type I 10.1.2.2 Type II 10.1.3 Bruker Corporation (U.S.) Small Animal Imaging Reagents Sales, Revenue, Price and Gross Margin (2011-2016) 10.1.4 Main Business/Business Overview 10.2 Siemens AG (Germany) 10.2.1 Company Basic Information, Manufacturing Base and Competitors 10.2.2 Small Animal Imaging Reagents Product Type, Application and Specification 10.2.2.1 Type I 10.2.2.2 Type II 10.2.3 Siemens AG (Germany) Small Animal Imaging Reagents Sales, Revenue, Price and Gross Margin (2011-2016) 10.2.4 Main Business/Business Overview 10.3 Life Technologies Corporation (U.S.) 10.3.1 Company Basic Information, Manufacturing Base and Competitors 10.3.2 Small Animal Imaging Reagents Product Type, Application and Specification 10.3.2.1 Type I 10.3.2.2 Type II 10.3.3 Life Technologies Corporation (U.S.) Small Animal Imaging Reagents Sales, Revenue, Price and Gross Margin (2011-2016) 10.3.4 Main Business/Business Overview 10.4 FUJIFILM Holdings Corporation (Japan) 10.4.1 Company Basic Information, Manufacturing Base and Competitors 10.4.2 Small Animal Imaging Reagents Product Type, Application and Specification 10.4.2.1 Type I 10.4.2.2 Type II 10.4.3 FUJIFILM Holdings Corporation (Japan) Small Animal Imaging Reagents Sales, Revenue, Price and Gross Margin (2011-2016) 10.4.4 Main Business/Business Overview 10.5 Miltenyi Biotec GmbH (Germany) 10.5.1 Company Basic Information, Manufacturing Base and Competitors 10.5.2 Small Animal Imaging Reagents Product Type, Application and Specification 10.5.2.1 Type I 10.5.2.2 Type II 10.5.3 Miltenyi Biotec GmbH (Germany) Small Animal Imaging Reagents Sales, Revenue, Price and Gross Margin (2011-2016) 10.5.4 Main Business/Business Overview 10.6 PerkinElmer, Inc. (U.S.) 10.6.1 Company Basic Information, Manufacturing Base and Competitors 10.6.2 Small Animal Imaging Reagents Product Type, Application and Specification 10.6.2.1 Type I 10.6.2.2 Type II 10.6.3 PerkinElmer, Inc. (U.S.) Small Animal Imaging Reagents Sales, Revenue, Price and Gross Margin (2011-2016) 10.6.4 Main Business/Business Overview 10.7 Bioscan, Inc. (U.S.) 10.7.1 Company Basic Information, Manufacturing Base and Competitors 10.7.2 Small Animal Imaging Reagents Product Type, Application and Specification 10.7.2.1 Type I 10.7.2.2 Type II 10.7.3 Bioscan, Inc. (U.S.) Small Animal Imaging Reagents Sales, Revenue, Price and Gross Margin (2011-2016) 10.7.4 Main Business/Business Overview 10.8 Mediso Medical Imaging Systems (Hungary) 10.8.1 Company Basic Information, Manufacturing Base and Competitors 10.8.2 Small Animal Imaging Reagents Product Type, Application and Specification 10.8.2.1 Type I 10.8.2.2 Type II 10.8.3 Mediso Medical Imaging Systems (Hungary) Small Animal Imaging Reagents Sales, Revenue, Price and Gross Margin (2011-2016) 10.8.4 Main Business/Business Overview 10.9 Gamma Medica (U.S.) 10.9.1 Company Basic Information, Manufacturing Base and Competitors 10.9.2 Small Animal Imaging Reagents Product Type, Application and Specification 10.9.2.1 Type I 10.9.2.2 Type II 10.9.3 Gamma Medica (U.S.) Small Animal Imaging Reagents Sales, Revenue, Price and Gross Margin (2011-2016) 10.9.4 Main Business/Business Overview 10.10 Aspect Imaging (Israel) 10.10.1 Company Basic Information, Manufacturing Base and Competitors 10.10.2 Small Animal Imaging Reagents Product Type, Application and Specification 10.10.2.1 Type I 10.10.2.2 Type II 10.10.3 Aspect Imaging (Israel) Small Animal Imaging Reagents Sales, Revenue, Price and Gross Margin (2011-2016) 10.10.4 Main Business/Business Overview Global QYResearch ( http://globalqyresearch.com/ ) is the one spot destination for all your research needs. Global QYResearch holds the repository of quality research reports from numerous publishers across the globe. Our inventory of research reports caters to various industry verticals including Healthcare, Information and Communication Technology (ICT), Technology and Media, Chemicals, Materials, Energy, Heavy Industry, etc. With the complete information about the publishers and the industries they cater to for developing market research reports, we help our clients in making purchase decision by understanding their requirements and suggesting best possible collection matching their needs.


SALEM, N.H.--(BUSINESS WIRE)--Gamma Medica, a leader in molecular breast imaging (MBI) technology, today announced it has partnered with Hospital Services Limited (HSL), an established medical device company that distributes, installs and services radiology capital equipment and medical devices. This partnership will provide women with dense breast tissue access to Gamma Medica’s LumaGEM® Molecular Breast Imaging system in the United Kingdom, Ireland and the Channel Islands. Women are eligible for the United Kingdom’s NHS breast screening programme at age 50-79 years, with women being invited to be screened every three years.1 Similarly in Ireland, women 50-69 years-old are eligible for breast screenings every two years.2 Dense breast tissue not only increases the risk of developing breast cancer, but decreases the visibility of a cancer on conventional mammograms and other forms of anatomical imaging devices. Dense breast tissue and cancer both appear white on mammograms making it difficult to distinguish between the two—it’s like trying to find a snowflake in a snowstorm. This may lead to false negatives, unwarranted biopsies or delayed diagnoses.3 Ideal for dense breast tissue, MBI is a groundbreaking technology that significantly improves early detection of breast cancer in women with dense breast tissue. The technology has proven to be as effective as a secondary screening method compared to ultrasound or MRI with far fewer false positives.4 Peer-reviewed clinical research reports the use of LumaGEM MBI reduces the need for tissue biopsies by 50 percent compared to other modalities.4 MBI is also more comfortable and better tolerated by most patients than conventional mammography or MRI. “We are pleased that through our collaboration with HSL, women with dense breasts in the UK, Ireland and the Channel Islands, will soon have access to the LumaGEM MBI technology,” said Philip Croxford, Gamma Medica President and CEO. “This partnership is the first step in Gamma Medica’s global expansion to increase awareness and access to clinical superior breast imaging technology worldwide. Leveraging HSL’s network enables Gamma Medica to continue to promote early detection on an international scale.” A breakthrough retrospective study, which complemented earlier published prospective clinical research, was published in the American Journal of Roentgenology’s August issue.5 This retrospective study monitored over 1,700 women with dense breast tissue over a three-year period. The study confirmed LumaGEM’s additional cancer detection rate of 7.7 cancers per 1,000, an increase from three cancers per 1,000 with mammography alone. The study also concluded that of the additional breast cancers found, approximately 85 percent of these cancers were invasive and node negative, indicating they were detected at an early stage and therefore presented the patient with the likelihood of a better prognosis.6 “Hospital Services Limited distributes market-leading technology and we are thrilled to add Gamma Medica’s LumaGEM Molecular Breast Imaging to our product offerings for our clients,” said Dominic Walsh, CEO of Hospital Services Limited. “Introducing Gamma Medica to the European market will enable women outside of the United States to receive the early detection technology they need. We’re excited to be Gamma Medica’s partner in this endeavor.” Gamma Medica launched the Be Certain campaign in the United States to raise awareness about breast density and breast cancer screening options. By sharing patient and physician testimonials, breast density facts and statistics and the latest news relating to breast density and breast screenings, the educational website aims to provide the most accurate information for physicians, patients and caregivers. For more information about breast density and screening options, visit www.becertain.info. About Gamma Medica, Inc. Gamma Medica, Inc. is a women’s health company focused on overcoming the limitations of anatomical imaging experienced by mammography and other screening modalities in the early detection of breast cancer. The company’s LumaGEM® MBI system is the first commercially available, FDA-cleared, fully solid-state digital imaging system utilizing dual-head Digital Direct Conversion Gamma Imaging™ (DDCGI™) technology for molecular breast imaging. With over 90 percent sensitivity and specificity, LumaGEM MBI has been shown to significantly improve cancer detection in women with dense breast tissue with fewer false positives relative to anatomical imaging technologies, such as MRI and whole breast ultrasound. For more information visit, www.gammamedica.com. About Hospital Services Limited Hospital Services Limited (HSL) is a leading provider of products & services to the healthcare sector in both Ireland and the UK. HSL’s Radiology division has over 50 years’ experience working within this diagnostic imaging arena. HSL offers unprecedented levels of quality products, services and technical assistance. HSL representatives with extensive imaging experience, supply products and support to all levels of medical staff with a major focus on providing quality service to the individual customer, whilst manufacturer trained engineers ensure equipment is maintained to exacting standards. HSL is committed to sourcing the latest technologies available to help provide peace of mind to patients and physicians alike while utilising cutting edge diagnostic tools. 1 Gov.uk, Breast Screening: Programme Overview, 2015. https://www.gov.uk/guidance/breast-screening-programme-overview 2 BreastCheck. http://www.breastcheck.ie/ 3 Mayo Clinic. Tests and Procedures Mammogram. http://www.mayoclinic.org/tests-procedures/mammogram/in-depth/dense-breast-tissue/art-20123968?pg=2 4 Rhodes DJ, Hruska CB, Conners AL, et al. JOURNAL CLUB: Molecular Breast Imaging at Reduced Radiation Dose for Supplemental Screening in Mammographically Dense Breasts. American Journal of Roentgenology. 2015;204(2):241-251. 5 Rhodes DJ, Hruska CB, Conners AL, et al. JOURNAL CLUB: Molecular Breast Imaging at Reduced Radiation Dose for Supplemental Screening in Mammographically Dense Breasts. American Journal of Roentgenology. 2015;204(2):241-251. 6 Shermis RB, Wilson KD, Doyle MT, Martin TS, Merryman D, Kudrolli H, Brenner RJ. Supplemental Breast Cancer Screening with Molecular Breast Imaging for Women with Dense Breast Tissue. American Journal of Roentgenology. 2016;207: 1-8. doi:10.2214/AJR15.15924.


CHICAGO--(BUSINESS WIRE)--Gamma Medica, a leader in molecular breast imaging (MBI) technology, today announced several 2016 achievements for its LumaGEM Molecular Breast Imaging system at this year’s Radiological Society of North America (RSNA) annual meeting (booth #2871). Over the past year, this MBI system has grown in national prominence and expanded its user base through a major educational campaign on breast density called Be Certain and by driving irrefutable clinical results featured in


News Article | November 1, 2016
Site: www.newsmaker.com.au

Mammography refers to a standard diagnostic and screening technique that is used to screen breast tissues for the presence of malignant tumor. Mammography involves the use of low-energy X-rays for early detection of breast cancer. On the basis of technology used, the mammography market can be classified as film-screen or digital. Initially, conventional screen-film mammography (SFM) was the only technique available in the market, which involved high-spatial resolution for producing images. Film cassettes are used in screen-film mammography, while electronic x-ray detectors are used in digital mammography; better images can be obtained using the latter. In digital mammography, photons are converted to light, which travels to a device that converts this into a digital signal to display on a computer monitor. The global market for mammography is expected to increase at a significant rate. This is due to increasing prevalence of breast cancer cases and rising awareness about the same. The market for mammography is highly regulated. Various acts have been passed worldwide, such as the Mammography Quality Standards Act (MQSA) to ensure good quality care in mammography. North America dominates the global market for mammography due to technical advancements in the field of diagnostic imaging and high prevalence of breast cancer in the region. Moreover, increased awareness about advantages of cancer detection in early stages and improved healthcare facilities are driving the market for mammography in North America. Over the next few years, the market for mammography in Asia is expected to experience high growth rate, followed by that in Europe. China and India are expected to be the fastest growing markets in Asia. This is due to the large population base and increasing prevalence of breast cancer cases in these countries. Some of the key driving forces of the mammography market in emerging economies are increasing awareness and improved healthcare facilities. Elderly people and patients suffering from hormonal disorders are at high risk of breast cancer. For instance, menopausal hormone therapy increases risk of breast cancer. Various factors such as rising geriatric population and increasing number of cases of hormonal misbalances are expected to drive the global market for mammography. Moreover, increasing awareness about mammography techniques is expected to drive this market. However, factors such as lack of awareness, discomfort to the patients, and side effects associated with mammography are restraining the market growth. Furthermore, lack of accurate results is also limiting the growth of the global market for mammography. Growing demographics and economies in developing countries such as India and China are expected to offer good opportunities for the global mammography market. This is due to increasing awareness and rising adoption rate of mammography techniques in these regions. Innovative new products with fewer side effects are expected to drive the global mammography market. However, changing health regulations imposed by various governments and availability issues could be major challenges for this market. Rising number of mergers and acquisitions and new product launches are some of the latest trends in the global mammography market. Major companies in the global mammography market include GE Healthcare, Koninklijke Philips N.V., Hologic, Inc and Gamma Medica, Inc. Some other companies having significance presence in this market are Siemens Healthcare, Toshiba Corporation, and SonoCiné, Inc.


A calibration rig and calibration method for an imaging system includes a base and a holder extending from the base, the holder including a fixture configured to hold a radioactive source material in a two-dimensional geometric configuration and a radioactive source material disposed in the fixture.


News Article | May 19, 2015
Site: www.businesswire.com

LONDON--(BUSINESS WIRE)--Racepoint Global, an integrated marketing communications agency at the intersection of influence and action, announced today the addition of seven innovative healthcare brands to the agency’s client roster, ranging from healthcare technology, life sciences, diagnostics and imaging to telehealth brands. Racepoint will be conducting various programmes for these clients, from earned media efforts and influencer mapping to website redesign, content development, disease education and patient communications. “We are seeing a direct correlation between the growth of the healthcare industry and the need for brands to engage agencies like Racepoint to help them differentiate with powerful narratives and positions around market drivers like the NHS reforms in the UK and the Affordable Care Act in the US,” said Peter Prodomou, President at Racepoint Global. “Racepoint’s experienced healthcare team continually tracks the evolution of key trends such as the adoption of value-based care, patient engagement, better coordination of care across the healthcare supply chain and improved clinical outcomes. Our healthcare experts understand the unique requirements of communicating in a regulated industry, helping each client build an unshakable presence with a thought leadership voice and position.” “We chose Racepoint Global because they immediately understood that we didn’t want to hire a PR firm just for the sake of having PR,” said Tom Ferry, president & CEO, Curaspan. “As a first time exhibitor at HIMSS, it was important for us to collaborate with an agency that is familiar with the show, has established media relationships and experience elevating a niche brand to a national audience. The Racepoint Global team secured more than a dozen HIMSS briefings and we’re looking forward to building off of that success.” New Racepoint Global client partnerships in the UK and US include: About Racepoint Global Racepoint Global is an integrated marketing communications agency that puts brands at the intersection of influence and action. Our powerful combination features the best in digital marketing, strategy, public relations and stakeholder communications. We start with a powerful story, then create, distribute, and activate content in places people naturally engage, affecting opinion, shaping perception, and driving decisions. To do this, we draw on a powerful network of earned and paid influencers, a deep partner network, and self-published, wholly-owned, and unbranded communities. Clients in technology, healthcare, life sciences, consumer, public policy and public affairs depend on Racepoint Global’s unique approach to impact key outcomes. Time again, our approach drives better results for our clients. For more information, visit www.racepointglobal.com.


News Article | May 19, 2015
Site: www.businesswire.com

BOSTON--(BUSINESS WIRE)--Racepoint Global, an integrated marketing communications agency at the intersection of influence and action, announced today the addition of seven innovative healthcare brands to the agency’s client roster, ranging from healthcare technology, life sciences, diagnostics and imaging to telehealth brands. Racepoint will be conducting various programs for these clients, from earned media efforts and influencer mapping to website redesign, content development, disease education and patient communications. “We are seeing a direct correlation between the growth of the healthcare industry and the need for brands to engage agencies like Racepoint to help them differentiate with powerful narratives and positions around market drivers like the ACA and meaningful use,” said Palmer Reuther, EVP & Boston Practice Lead, Racepoint Global. “Racepoint’s experienced healthcare team continually tracks the evolution of key trends such as the adoption of value-based care, patient engagement, better coordination of care across the healthcare supply chain and improved clinical outcomes. Our healthcare experts understand the unique requirements of communicating in a regulated industry, helping each client build an unshakable presence with a thought leadership voice and position.” “We chose Racepoint Global because they immediately understood that we didn’t want to hire a PR firm just for the sake of having PR,” said Tom Ferry, president & CEO, Curaspan. “As a first time exhibitor at HIMSS, it was important for us to collaborate with an agency that is familiar with the show, has established media relationships and experience elevating a niche brand to a national audience. The Racepoint Global team secured more than a dozen HIMSS briefings and we’re looking forward to building off of that success.” New Racepoint Global client partnerships in the UK and US include: About Racepoint Global Racepoint Global is an integrated marketing communications agency that puts brands at the intersection of influence and action. Our powerful combination features the best in digital marketing, strategy, public relations and stakeholder communications. We start with a powerful story, then create, distribute, and activate content in places people naturally engage, affecting opinion, shaping perception, and driving decisions. To do this, we draw on a powerful network of earned and paid influencers, a deep partner network, and self-published, wholly-owned, and unbranded communities. Clients in technology, healthcare, life sciences, consumer, public policy and public affairs depend on Racepoint Global’s unique approach to impact key outcomes. Time again, our approach drives better results for our clients. For more information, visit www.racepointglobal.com .


News Article | May 19, 2015
Site: www.businesswire.com

BOSTON--(BUSINESS WIRE)--Racepoint Global, an integrated marketing communications agency at the intersection of influence and action, announced today the addition of seven innovative healthcare brands to the agency’s client roster, ranging from healthcare technology, life sciences, diagnostics and imaging to telehealth brands. Racepoint will be conducting various programs for these clients, from earned media efforts and influencer mapping to website redesign, content development, disease education and patient communications. “We are seeing a direct correlation between the growth of the healthcare industry and the need for brands to engage agencies like Racepoint to help them differentiate with powerful narratives and positions around market drivers like the ACA and meaningful use,” said Palmer Reuther, EVP & Boston Practice Lead, Racepoint Global. “Racepoint’s experienced healthcare team continually tracks the evolution of key trends such as the adoption of value-based care, patient engagement, better coordination of care across the healthcare supply chain and improved clinical outcomes. Our healthcare experts understand the unique requirements of communicating in a regulated industry, helping each client build an unshakable presence with a thought leadership voice and position.” “We chose Racepoint Global because they immediately understood that we didn’t want to hire a PR firm just for the sake of having PR,” said Tom Ferry, president & CEO, Curaspan. “As a first time exhibitor at HIMSS, it was important for us to collaborate with an agency that is familiar with the show, has established media relationships and experience elevating a niche brand to a national audience. The Racepoint Global team secured more than a dozen HIMSS briefings and we’re looking forward to building off of that success.” New Racepoint Global client partnerships in the UK and US include: About Racepoint Global Racepoint Global is an integrated marketing communications agency that puts brands at the intersection of influence and action. Our powerful combination features the best in digital marketing, strategy, public relations and stakeholder communications. We start with a powerful story, then create, distribute, and activate content in places people naturally engage, affecting opinion, shaping perception, and driving decisions. To do this, we draw on a powerful network of earned and paid influencers, a deep partner network, and self-published, wholly-owned, and unbranded communities. Clients in technology, healthcare, life sciences, consumer, public policy and public affairs depend on Racepoint Global’s unique approach to impact key outcomes. Time again, our approach drives better results for our clients. For more information, visit www.racepointglobal.com .

Loading Gamma Medica collaborators
Loading Gamma Medica collaborators